Elizabeth Hurlburt serves as the Executive Vice President, Chief Clinical Strategy and Operations Officer at CORMEDIX INC, a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. In her role, Hurlburt is responsible for overseeing the clinical strategy and operations of the company, ensuring that CORMEDIX's products meet the highest standards of safety and efficacy. Her leadership has been instrumental in guiding the company through the complex landscape of clinical trials and regulatory approvals. Hurlburt brings a wealth of experience to her position, with a distinguished career in the pharmaceutical and biotechnology industries. Prior to joining CORMEDIX, she held various leadership roles at several prominent companies, where she demonstrated a keen ability to drive successful clinical programs and bring innovative therapies to market. Her expertise in clinical development, regulatory affairs, and strategic planning has been recognized throughout the industry, and she has been a key contributor to the advancement of numerous groundbreaking treatments. Under Hurlburt's guidance, CORMEDIX has made significant strides in its mission to improve patient outcomes and address unmet medical needs. Her strategic vision and operational excellence have been critical in navigating the challenges of drug development and commercialization. Hurlburt's dedication to the company's goals, combined with her extensive knowledge and experience, make her an invaluable asset to CORMEDIX as it continues to grow and expand its portfolio of life-saving therapies.